ENIGMA-TRS 2 is a global, randomized, double-blind, placebo-controlled 12-week Phase III clinical study designed to enroll at least 400 patients; topline results are expected by Q4 2026 Evenamide is a ...
Newron Pharmaceuticals (SWX:NWRN) just kicked off its ENIGMA TRS 2 Phase III trial in the US, a key late stage step for Evenamide in treatment resistant schizophrenia after securing FDA and IRB ...
Proceeds expected to fund global ENIGMA-TRS studies and extend cash runway beyond pivotal 12-week results, supporting development of evenamide as the potential first add-on therapy for ...
Newron Pharmaceuticals has announced the launch of its Phase III ENIGMA-TRS 2 trial in the US, marking an important step for the registrational programme for lead candidate evenamide in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results